ValuEngine cut shares of Genmab A/S (NASDAQ:GMAB) from a hold rating to a sell rating in a research report sent to investors on Wednesday, ValuEngine reports.

GMAB has been the topic of a number of other reports. Morgan Stanley assumed coverage on Genmab A/S in a report on Monday, August 12th. They issued an overweight rating on the stock. JPMorgan Chase & Co. upgraded Genmab A/S from a neutral rating to an overweight rating and set a $23.00 target price on the stock in a report on Thursday, September 12th. Royal Bank of Canada assumed coverage on Genmab A/S in a report on Monday, August 12th. They issued an outperform rating and a $23.00 target price on the stock. HC Wainwright increased their target price on Genmab A/S from $24.00 to $25.00 and gave the stock a buy rating in a report on Wednesday, October 16th. Finally, Guggenheim assumed coverage on Genmab A/S in a report on Monday, August 12th. They issued a buy rating on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $23.67.

Shares of GMAB traded down $0.22 during trading hours on Wednesday, reaching $22.06. The stock had a trading volume of 101,900 shares, compared to its average volume of 193,995. Genmab A/S has a 12 month low of $13.64 and a 12 month high of $22.35. The stock’s 50-day moving average is $20.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.72 and a quick ratio of 18.72. The firm has a market cap of $2.85 billion and a P/E ratio of 5.87.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, August 14th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.13. Genmab A/S had a return on equity of 16.26% and a net margin of 42.39%. The company had revenue of $116.49 million for the quarter. Sell-side analysts expect that Genmab A/S will post 0.53 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of GMAB. Parametric Portfolio Associates LLC bought a new position in Genmab A/S during the 2nd quarter valued at $6,937,000. Oppenheimer Asset Management Inc. bought a new position in Genmab A/S during the 3rd quarter valued at $4,788,000. Synovus Financial Corp bought a new position in Genmab A/S during the 3rd quarter valued at $2,876,000. Envestnet Asset Management Inc. bought a new position in Genmab A/S during the 3rd quarter valued at $2,698,000. Finally, Brinker Capital Inc. bought a new position in Genmab A/S during the 3rd quarter valued at $988,000. Institutional investors and hedge funds own 1.37% of the company’s stock.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Recommended Story: What are no-load funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.